Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 2/3 1

Status

Active not recruiting 3Withdrawn 1Recruiting 1

Sponsor Class

NIH 3OTHER 1NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 5Lymphoid 1

Conditions

Glioblastoma 12Prostatic Neoplasms 11Oropharyngeal Neoplasms 10Lung Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 9Glioma 8Urinary Bladder Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Esophageal Neoplasms 6Neoplasm Metastasis 5Mouth Neoplasms 5Carcinoma 5Burkitt Lymphoma 5Astrocytoma 5Sarcoma 4Pancreatic Neoplasms 4Laryngeal Neoplasms 4Gliosarcoma 4Carcinoma, Hepatocellular 4Brain Neoplasms 4Adenocarcinoma of Lung 4Adenocarcinoma Of Esophagus 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Rhabdomyosarcoma, Embryonal 3Rhabdomyosarcoma 3Rectal Neoplasms 3Neoplasms 3

Interventions

Specimen Handling 12Magnetic Resonance Spectroscopy 12Temozolomide 11Radiotherapy 8Radiation 5Surgical Procedures, Operative 3Biopsy 3trametinib 2dabrafenib 2Spinal Puncture 2Radiotherapy, Intensity-Modulated 2Genetic Therapy 2Craniotomy 2Bevacizumab 2vorasidenib 1vocimagene amiretrorepvec 1veliparib 1trastuzumab deruxtecan 1tocilizumab 1ribociclib 1pembrolizumab 1atezolizumab 1abexinostat 1Vorinostat 1Transurethral Resection of Bladder 1Standard of Care 1Restraint, Physical 1Protons 1Proton Therapy 1Practice Guidelines as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Astrocytoma × Radiation × 90 days × Clear all
NCT03581292 2026-05-27

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

National Cancer Institute (NCI)

Phase 2 Active not recruiting
38 enrolled 13 charts
CNS

Astrocytoma, Glioblastoma, Glioma

NCT03919071 2026-05-27

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
58 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma

NCT06894979 2026-05-15

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Children's Oncology Group

Phase 1 Recruiting
54 enrolled
CNS

Astrocytoma

NCT03528642 2026-05-13

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
40 enrolled
CNSLymphoid

Astrocytoma, Lymphoma, Follicular

NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡